HOME >> BIOLOGY >> NEWS
Virginia Bioinformatics Institute researcher receives USDA functional genomics grant

Blacksburg, Va. Brett Tyler, research professor at the Virginia Bioinformatics Institute (VBI) and Virginia Tech professor of plant pathology, physiology, and weed science, has been awarded a three-year, $980,000 grant from the U.S. Department of Agriculture (USDA) to identify the ways in which the plant pathogen Phytopthora sojae overcomes the defenses of its host soybean.

Phytophthora species and related pathogens cause tens of billions of dollars of damage every year to a wide range of both agriculturally and ornamentally important plants and also cause severe damage to forests and threaten entire natural ecosystems. More specifically, P. sojae causes serious damage to soybean crops and cost growers $1 billion worldwide in 2003. In order to develop improved methods for controlling Phytophthora infection, it is important to understand how these pathogens break down plants' defenses.

Many of the most important interactions between the pathogen and its host occur early in the infection process. Tyler and co-project director Kurt Lamour, assistant professor of entomology and plant pathology at the University of Tennessee, Knoxville, will focus on identifying and characterizing genes active at the earliest times during P. sojae infection, starting with spore germination and penetration of the host, and continuing through the first 16 hours of infection. This time period is the most crucial for a successful infection because this is when the pathogen seeks to establish itself within the host tissue. Collaborators Michael Scanlon at the University of Georgia, and Hayes McDonald at Oak Ridge National Laboratory also will assist in the study.

"A complex web of interactions between pathogen and plant genes occurs during the first hours of infection as the two organisms battle for supremacy," Tyler said. "By taking a whole genome approach that measures the activities of all the pathogen and plant genes simultaneously we can begin to tease apart this
'"/>

Contact: Susan Bland
subland@vbi.vt.edu
540-231-7912
Virginia Tech
12-Jul-2005


Page: 1 2

Related biology news :

1. Virginia Tech researchers to study poplar tree as model biomass crop
2. Fire ants are emerging nuisance for Virginians
3. Virginia Techs System X supercomputer provides super tool for simulation of cell division
4. Asian Soybean Rust found in Virginia, but not a threat to current crop
5. Virginia Tech chemists create new polymers by adding DNA base pairs
6. Pregnant drivers, football players safer thanks to a top Virginia Tech researcher
7. Virginia Tech student selected to meet Nobel Laureates
8. Virginia study urges early emphasis on science
9. Award supports Virginia Tech research to reduce vehicle emissions, create biofuel
10. Oswaldo Cruz Foundation, Virginia Bioinformatics Institute sign agreement...
11. Virginia Bioinformatics Institute to develop Tomato Metabolite Database

Post Your Comments:
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: